Instem plc Notice of Results and Investor Presentation (2457Y)

TIDMINS

RNS Number : 2457Y

Instem plc

03 May 2023

Instem plc

("Instem" or the "Company")

Notice of Results and Investor Presentation

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, will announce results for the year ended 31 December 2022 on Monday 15 May 2023.

Analyst Presentation: 09:30, Monday 15 May

Management will be hosting a presentation on the day of the results at 09:30 with CEO Phil Reason, CFO Nigel Goldsmith and Corporate Vice President Investor Relations Jon Horton. The presentation will be hosted both in person and via web conference for those unable to attend. Analysts wishing to join remotely or attend in person should register their interest by emailing [e-mail] or by telephoning 020 7933 8780.

IMC Presentation: 16:00, Monday 15 May

Management will be providing a presentation and hosting an Investor Q&A session on the results and future prospects at 16:00 on the day, through the digital platform Investor Meet Company. Investors can sign up for free and add to attend the presentation via the following link https://www.investormeetcompany.com/instem-plc/register-investor

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00 the day before the meeting or at any time during the live presentation.

For further information, please contact:

 
 Instem plc                                   Via Walbrook 
 Phil Reason, CEO 
 Nigel Goldsmith, CFO 
 
 Singer Capital Markets (Nominated Adviser 
  & Joint Broker)                             [phone] 
 Peter Steel 
  Alex Bond 
  Oliver Platts 
 
 Stifel Nicolaus Europe Limited (Joint 
  Broker)                                     [phone] 
 Ben Maddison 
 Alex Price 
  Richard Short 
 
 Walbrook Financial PR                        [phone] 
 Tom Cooper                                   [e-mail] 
 Nick Rome 
 Joe Walker 
 

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

To learn more about Instem solutions and its mission, please visit www.instem.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORSSFSIDEDSEDI

(END) Dow Jones Newswires

May 03, 2023 02:00 ET (06:00 GMT)